MentalHealthDaily

AI Levodopa Timing Improved UPDRS 4.4 Points in 5 Parkinson Patients

by GLOOM

MHD featured image for AI-guided levodopa dosing in Parkinson's disease.

A 2026 open-label feasibility trial involving 5 Parkinson’s disease patients found that app-randomized levodopa timing was associated with a mean 4.4-point improvement on the Unified Parkinson’s Disease Rating Scale, but the signal missed conventional statistical significance at p = 0.063.1 The narrow conclusion is feasibility: this was a dosing experiment that justified a blinded controlled …

77-Drug Blood Screen Found Benzodiazepines in 37.9% of Detections

by GLOOM

MHD featured image for neuropsychiatric drug blood screening and benzodiazepine detections.

A 2026 clinical-lab study tested a 77-drug liquid chromatography-tandem mass spectrometry serum screen in 1,021 patients and found that benzodiazepines accounted for 37.9% of all detections, ahead of antidepressants and antipsychotics.1 Emergency-department cases were a small slice of the sample, but they were positive more often than outpatients: 85.2% vs. 59.5%. Research Highlights Benzodiazepines dominated …